Cardiovascular
Peripartum Cardiomyopathy
5
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Peripartum Cardiomyopathy is an early-stage landscape with 5 programs across 1 company. The most active players are Neurim Pharmaceuticals Ltd.. 2 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Recruiting1 · 17%
Not yet recruiting1 · 17%
Withdrawn1 · 17%
Clinical Trials
Trial Activity
6 trials
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Recruiting·—·Phase 4·NCT05180773·250 enrolled
Peripartum Cardiomyopathy in Nigeria Registry
Completed·—·Phase 4·NCT03081949·100 enrolled
Taurine in Peripartum Cardiomyopathy
Completed·—·Phase 2/3·NCT03907267·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)